ANX-M1 (Human IgG1)

ANX-M1 is a blood-brain barrier-permeable anti- C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease ^{[1] [2]}.

In Vivo, ANX-M1 (7.5 μg/μL-100 mg/kg; intravitreal; single dose; intraperitoneal; days 0,4,8) protects against progressive retinal degeneration in C57BL/6J mice with photo-oxidative damage-induced retinal degeneration (with TUNEL+ photoreceptor cell death reduction, ONL thickness increase, ERG responses improvement, and serum complement hemolytic activity reduction of >50% for effective regimens)^[1].

References:
[1]. Jiao H, et al. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. Mol Neurodegener. 2018;13(1):45. Published 2018 Aug 20.
[2]. Gagnon M, et al. Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease. Molecules. 2023;28(13):5206. Published 2023 Jul 4.